| HOME >> BIOLOGY >> TECHNOLOGY |
SEP has established its own commercial operations in the UK, Germany, France and Italy and will market its products in other regions and territories through relationships with expert partners.
About Rottapharm-Madaus
Established in 1961, Rottapharm is a multinational pharmaceutical company primarily engaged in the research, development and global distribution of new pharmaceutical products in different therapeutic areas including rheumatology, cardiology, gastroenterology, gynaecology paediatrics, dermatology, urology, oncology, bronchopneumology, psychiatry.
The Headquarter and main R&D site are located in Italy.
Rottapharm has recently acquired the global German pharmaceutical Group Madaus Pharma and today the Rottapharm|Madaus Group has subsidiaries or direct commercial operations throughout Europe and in the vast majority of Middle East, Asia (excluding Japan) and Central/South America countries.
Current Rottapharm's main products include: the original Glucosamine Sulfate EU prescription product that paved the way for several nutraceutical glucosamines with yet unsurpassed clinical expertise in the development of Disease Modifying Drugs in Osteoarthritis; a line of matrix transdermal delivery systems for HRT and CVD; and others out of a list of 19 new drugs derived from over 300 patents. Moreover, the Group has recently implemented a line of effective and successful nutraceuticals for dyslipidemias, women's health, inflammation, and entered the area of personal care that includes a line of leading products in intimate hygiene/paediatric/skin care and in which the company is ranked as the sixth largest in the world market.
Finally, with the acquisition of
'/>"/>
| SOURCE Speciality European Pharma Copyright©2009 PR Newswire. All rights reserved |